Albert Labs International (FRA:VB50) Common Stock: €5.62 Mil (As of Sep. 2023)


What is Albert Labs International Common Stock?

Albert Labs International FRA:VB50 Common Stock is €5.62 Mil as of Sep. 2023.

Albert Labs International's quarterly common stock increased from Mar. 2023 (€5.55 Mil) to Jun. 2023 (€5.64 Mil) but then declined from Jun. 2023 (€5.64 Mil) to Sep. 2023 (€5.62 Mil).

Albert Labs International's annual common stock increased from . 20 (€0.00 Mil) to Dec. 2021 (€1.25 Mil) and increased from Dec. 2021 (€1.25 Mil) to Dec. 2022 (€5.53 Mil).

Albert Labs International Common Stock Historical Data

* Premium members only.

The historical data trend for Albert Labs International's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International Common Stock Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Common Stock
1.25 5.53

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.95 5.53 5.55 5.64 5.62

Albert Labs International Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €5.62 Mil mean?
Albert Labs International (FRA:VB50) has a Common Stock of €5.62 Mil as of Sep. 2023. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Albert Labs International and its competitors.
Is Albert Labs International's Common Stock too high?
Albert Labs International's current Common Stock is €5.62 Mil.
How does Albert Labs International's Common Stock compare to VRTX and REGN?
Albert Labs International's Common Stock of €5.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Albert Labs International and its competitors. Albert Labs International's current Common Stock is €5.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current Common Stock of €5.62 Mil. The current Common Stock is €5.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current Common Stock is €5.62 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.